Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Jagsonpal Pharmaceuticals
Small Cap•1,025 Employees•IPO 1996
Current Price
₹182.96
-6.65 (-3.51%)Updated
Today's Range
181.99
₹182.96
193.9
52 Week Range
52W Low₹155.00
52W High₹301.65
₹182.96
Downside18.04%
Upside64.87%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹1,178.94 Cr
Market Cap
Total market value of companyP/E Ratio
28.36
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
5.78
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹6.07
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
7.77%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
23.00%
ROCE
Return on Capital Employed. >15% is goodNet Margin
14.53%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
22.31%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
11.13%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
23.10%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
38.60%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.04
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹36.14
Book Value
Net asset value per shareDividend Yield
1.44%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
67.60%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •ROCE at 23.00% and ROE at 18.60% indicate efficient capital utilization and strong returns for shareholders, reflecting robust operational performance.
- •The company reported a significant 23.10% increase in quarterly sales and a substantial 38.60% rise in quarterly net profit, demonstrating strong recent business momentum.
Weaknesses
4 points- •The stock is trading near its 52-week low of 192.85, a substantial drop from its 52-week high of 820.10, indicating considerable price volatility and potential investor concern.
- •A price-to-book value of 6.15 suggests the stock is trading at a premium relative to its intrinsic asset value, which might limit upside potential for value investors.
Opportunities
4 points- •Operating in the "Pharmaceuticals" sector, the company can capitalize on the broader industry expansion driven by increasing healthcare demand, R&D, and global market access.
- •The gradual increase in FII holding from 0.00% in 2022-06-01 to 2.12% in 2025-09-01 indicates growing foreign investor interest, potentially attracting more capital.
Threats
4 points- •The company faces stiff competition from larger, more established players like Sun Pharma, Divi's Lab, and Cipla, which have significantly higher market caps and resources.
- •The company's P/E of 34.80 is below the sector P/E of 41.06, potentially indicating that the market values its growth prospects less favorably than the overall industry.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹214.40 | +₹31.44 | +17.18% |
| R3 | ₹202.49 | +₹19.53 | +10.67% |
| R2 | ₹198.19 | +₹15.23 | +8.33% |
| R1 | ₹190.58 | +₹7.62 | +4.16% |
| PIVOT | ₹186.28 | 3.32 | 1.82% |
| CURRENT | ₹182.96 | - | - |
| S1 | ₹154.85 | -₹28.11 | -15.37% |
| S2 | ₹166.76 | -₹16.20 | -8.86% |
| S3 | ₹174.37 | -₹8.59 | -4.69% |
| S4 | ₹178.67 | -₹4.29 | -2.35% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+127.6% vs avg
6.49L
(13 Mar 2026)Delivery %+1.0% vs avg
54.0%
(13 Mar 2026)Avg Volume (20D)20-day average
2.85L
(13 Feb - 13 Mar)Avg Delivery %Trend ↓
53.0%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Ind-Swift Laboratories Ltd
833.00 %
Highest Dividend Yield
Anuh Pharma Ltd
1.85 %
Peer Comparison
| Company Name |
|---|
 Amrutanjan Health Care Ltd |
 Anuh Pharma Ltd |
 Bajaj Healthcare Ltd |
 Beta Drugs Ltd |
 Bliss GVS Pharma Ltd |
 Ind-Swift Laboratories Ltd |
 Lincoln Pharmaceuticals Ltd |
 NGL Fine Chem Ltd |
 Sakar Healthcare Ltd |
 Sigachi Industries Ltd |
 Sun Pharmaceutical Industries Ltd |
 Syncom Formulations (India) Ltd |
 Themis Medicare Ltd |
 TTK Healthcare Ltd |
 Venus Remedies Ltd |
About
Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) is a pharmaceutical company primarily operating in India but also with an international presence. Their core business revolves around the manufacturing, sale, and trading of pharmaceutical products and active pharmaceutical ingredients (APIs).
The company's product portfolio spans a variety of therapeutic areas, with a notable focus on gynecology, orthopedics, dermatology, and pediatrics. This specialization allows them to cater to a diverse range of patient needs and healthcare requirements.
JAGSNPHARM offers its products in multiple dosage forms, including tablets, softgels, injections, capsules, and syrups. This diverse range of delivery methods enables flexibility in addressing various patient preferences and treatment requirements. The variety of forms also suggests a broad range of active ingredients and formulations within their product lines.
Their customer base includes both healthcare professionals, such as doctors and pharmacists, and government institutions. This dual market approach signifies a robust and diversified distribution network, lessening dependence on any single customer segment. The inclusion of government institutions suggests a presence in public health initiatives and contracts.
Established in 1978 and headquartered in New Delhi, India, JAGSNPHARM benefits from a long operational history in the Indian pharmaceutical market. This longevity suggests established supply chains, manufacturing capabilities, and regulatory compliance.
COMPANY FACTS - JAGSNPHARM
Registered Address
Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar Sec-18
Gurgaon
HARYANA
IN
Tel: 911244406710
Website:https://www.jagsonpal.com/
Investor Relations:http://www.jagsonpal.com/investor-relations
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,025
IPO Date: 13/09/1996
MANAGEMENT - JAGSNPHARM
Mr. Rajpal Kochhar
Chairman of the Board, Managing Director
Mr. Sachin Jain
Chief Financial Officer
Mr. Pratham Rawal
Compliance Officer, Company Secretary
Mr. Manish Gupta
Managing Director, Additional Director
Mr. Prithipal Kochhar
Non-Executive Additional Director
Mr. Harsha Raghavan
Non- Executive Additional Director
Ms. Radhika Dudhat
Non-Executive Additional Independent Director
Ms. Pallavi Gupta
Non-Executive Additional Independent Director
Mr. Debasis Nandy
Non-Executive Additional Independent Director
Investor Questions Answered
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) Stock FAQs
Get answers to the most common questions about Jagsonpal Pharmaceuticals Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹182.96. Today, the stock has declined by ₹6.65 (3.51%), trading in a range of ₹181.99 to ₹193.9. The stock opened at ₹191.9 with a trading volume of 6,49,002 shares.
Jagsonpal Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,178.94 crores, P/E ratio of 28.36, ROE of 7.77%, and ROCE of 23.00%. The dividend yield stands at 1.44%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹301.65, while the 52-week low is ₹155. Currently trading at ₹182.96, the stock is 19.1% away from its 52-week low and 39.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Jagsonpal Pharmaceuticals Ltd stock at ₹182.96 depends on multiple factors. The stock is currently trading with a P/E ratio of 28.36 and P/B ratio of N/A. Today's performance shows a loss of 3.51%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Jagsonpal Pharmaceuticals Ltd offers a dividend yield of 1.44%, which means for every ₹100 invested at the current price of ₹182.96, you can expect to receive approximately ₹1.44 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Jagsonpal Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 28.36, P/B Ratio: N/A, ROE: 7.77%, ROCE: 23.00%, Dividend Yield: 1.44%, EPS: ₹6.07, Book Value: ₹36.14, Debt-to-Equity: 0.04, and Current Ratio: N/A. The company's market cap stands at ₹1,178.94 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Jagsonpal Pharmaceuticals Ltd stock opened at ₹191.9 and is currently trading at ₹182.96, showing a decline of ₹6.65 (3.51%). The intraday high is ₹193.9 and low is ₹181.99. The trading volume stands at 6,49,002 shares, indicating moderate market participation today.
Jagsonpal Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 28.36, which means investors are willing to pay ₹28.36 for every ₹1 of earnings. With an EPS of ₹6.07, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Jagsonpal Pharmaceuticals Ltd has a market capitalization of ₹1,178.94 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹182.96) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Jagsonpal Pharmaceuticals Ltd has a book value of ₹36.14 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹182.96, which is 406.3% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Jagsonpal Pharmaceuticals Ltd has a Return on Equity (ROE) of 7.77% and Return on Capital Employed (ROCE) of 23.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Jagsonpal Pharmaceuticals Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Jagsonpal Pharmaceuticals Ltd has a debt-to-equity ratio of 0.04, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Jagsonpal Pharmaceuticals Ltd has an Earnings Per Share (EPS) of ₹6.07, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹182.96 and P/E ratio of 28.36, investors are paying 28.36 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Jagsonpal Pharmaceuticals Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Jagsonpal Pharmaceuticals Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Jagsonpal Pharmaceuticals Ltd stock, consider: 1) Fundamental Analysis - Review P/E (28.36), ROE (7.77%), debt-to-equity (0.04), and growth rates. 2) Technical Analysis - Check 52-week range (₹155.00 - ₹301.65), moving averages, and chart patterns. 3) Valuation - Compare current price (₹182.96) with book value (₹36.14) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Jagsonpal Pharmaceuticals Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹182.96 is 9048x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Jagsonpal Pharmaceuticals Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹155.00 - ₹301.65). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.04 indicates leverage. 4) Liquidity Risk - Based on trading volume of 6,49,002 shares. 5) Valuation Risk - P/E of 28.36 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Jagsonpal Pharmaceuticals Ltd operates in the industry with key metrics: P/E ratio of 28.36, ROE of 7.77%, market cap of ₹1,178.94 crores, and dividend yield of 1.44%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.04), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Jagsonpal Pharmaceuticals Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹182.96, with a 52-week range of ₹155.00 to ₹301.65. Based on fundamentals like P/E (28.36), ROE (7.77%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Jagsonpal Pharmaceuticals Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹182.96. 2) Fundamental Deterioration - Declining ROE (currently 7.77%), increasing debt (D/E: 0.04), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Jagsonpal Pharmaceuticals Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 1.44%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu